you're welcome to short sell this stock if you believe it's going to go back down to $17.50. You might make a bit of money since share prices never go up in a straight line over the long term. But I wouldn't like to be exposed being short when the next lot of results are released in the Q2 of '24 for 2591's PhII trials for Pitt-Hopkins syndrome. Or when the next quarterly report is issued by Acadia showing the growth in revenue from Daybue sales. Or when our next 2C report is issued at the end of Jan '24 showing the growth in revenue from royalties on Daybue sales, and possibly even another milestone payment is received. There's simply too much good news likely to come through the pipeline over the next 2 - 6 months. But no doubt, during that time there may be some dips below $20 to give buyers another entry opportunity. That won't bother me in the slightest as I'm already up 260% on my accumulation over the last 10 years.
NEU Price at posting:
$21.16 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)